The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy

NCT06425419 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Proliferative Vitreoretinopathy
Proliferative Vitreo-Retinopathy
Rhegmatogenous Retinal Detachment

Interventions

DRUG: Topotecan

Sponsor

Massachusetts Eye and Ear Infirmary